Excellent reliability of the six-minute walking distance measured	by 4
FeetMe [®] insoles at home.	5
Andrey Mostovov ^{1,*} , Damien Jacobs ¹ , Leila Farid ¹ , Paul Dhellin ¹ , and Guillaume Baille ²	6 7
¹ FeetMe [®] SAS, 157 bd. MacDonald, Paris, France	8 9
² Neurology department, Delafontaine Hospital Center, Saint-Denis, France; guillaume.baille@ch-stdenis.fr	10
* Correspondence: <u>science@feetme.fr</u> (AM)	11
	12

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1

2

Abstract

Background

Wearable technology provides an opportunity for new ways of monitoring patient gait remotely, through at-home selfadministered six-minute walk tests (6MWTs). The purpose of this study was to evaluate the reliability and repeatability of FeetMe[®] insoles, a wearable gait assessment device, for measuring the six-minute walking distance (6MWD) during tests conducted independently at home by healthy volunteers.

Methods

Participants (n=21) performed two 6MWTs at home while wearing the FeetMe[®] insoles, and two 6MWTs at hospital 20 while wearing FeetMe[®] insoles and being assessed by a rater. All assessments were performed with a one-week interval 21 between tests, no assistance was provided to the participants at home. 22

Results and conclusion

The agreement between the 6MWD measurements made at baseline and at Week 1 was good for all test configurations 24 and was highest for the at-home FeetMe[®] measurements, with an intraclass correlation coefficient (ICC) of 0.95, 25 standard error of the measurement (SEM) of 15.02 m and coefficient of variation (CV) of 3.33%, compared to ICCs of 26 0.79 and 0.78, SEMs of 25.65 and 26.65 and CVs of 6.24% and 6.10% for the rater and FeetMe[®] measurements at 27 hospital, respectively. Our work demonstrates that the FeetMe[®] system could provide a reliable solution allowing 28 individuals to self-administer 6MWTs independently at home.

Author Summary

At-home patients monitoring using wearable tools presents numerous advantages for regular care and clinical studies. 31 Patients benefit from the convenience of not having to travel to a clinic for assessments, which is particularly helpful 32 for those in remote areas or with mobility issues. Besides, at-home monitoring allows for more frequent assessments, 33 leading to more accurate clinical decision-making and timely intervention, which ultimately results in enhanced patient 34 care. For the same reasons, it can improve patients recruitment and retention in clinical studies. 35

The six-minute walk test (6MWT) is a commonly used standardized assessment of functional capacity in patients with 36 various diseases. We evaluated the reliability and repeatability of FeetMe® insoles, a wearable gait assessment device, 37 for measuring the six-minute walking distance (6MWD) at home. Our analysis of the data from 21 healthy volunteers 38

13

14

- 19
- 23

showed that the FeetMe[®] insoles were as reliable at home as they were in the standard clinical setting and as a 39 conventional way of assessing the 6MWD. In addition, the insoles provided extensive gait analysis, which may allow 40 for more precise conclusions regarding the patient's state and its evolution than the 6MWD alone. We conclude that the 41 FeetMe[®] device is an excellent tool for at-home patients monitoring. 42

Introduction

43

Gait is considered as a reliable indicator of overall health status. A range of conditions, such as neurological diseases, can lead to gait impairment including a slow gait speed, gait asymmetry, and an 45 unbalanced center of gravity [1,2]. Several tests have been developed to evaluate these parameters, such as 46 the two-minute walking test (2MWT) [3], the six-minute walking test (6MWT) [4], and the twelve-minute 47 walking test (12MWT) [5]. Among these tests, the 6MWT is the most widely used assessment and has 48 emerged as the "go-to" gait evaluation test in clinical practice. It is easy to administer and well tolerated, and 49 has been found to provide a better reflection of a patient's capacity for daily physical activity than other tests 50[4]. The test involves measuring the distance walked by a patient during a 6-minute time frame (i.e., the six-51 minute walking distance; 6MWD). It has been used conclusively in many clinical investigations. The test-52 retest reliability of the 6MWT has been found to be excellent, with reported intraclass correlation coefficients 53 (ICCs) of 0.91-0.98 and inter- and intra-rater reliability ICCs of 0.86-0.96 [6–8]. 54

Despite its many advantages, the 6MWT does have some limitations that need to be addressed. First, the test is typically carried out and monitored manually by a rater, which may lead to bias. Most notably, words of encouragement [9] or variations in the instructions provided by the rater [10] could impact the patient's performance. Second, the test only evaluates a single gait parameter (the average gait speed over 6 minutes); whereas other gait parameters, such as stride length or stance time, have been shown to be useful for evaluating patient health status. Indeed, such gait parameters have been shown to be valuable indicators of fatigue in 60 patients with multiple sclerosis [11].

The development of wearable technology has provided new opportunities for enhancing the monitoring of gait in patients with a range of diseases. In particular, exploring whether wearable devices could be used to

allow gait assessments to be conducted at home could be highly beneficial for patients. Self-administering gait 64 tests at home could eliminate the patient burden associated with commuting to clinical facilities. At-home 65 monitoring would also allow for repeated tests to be conducted over an extended period of time, allowing 66 physicians to gather more longitudinal data and improve patient follow-up. Several research groups have 67 proposed ways to evaluate gait parameters in the comfort of the patient's own home. Studies testing the 68 reliability of an accelerometer-based quantification program [12] and a wearable guided 6MWT device [13] 69 to measure gait speed in patients with cardiovascular conditions have obtained promising results, with the at-70 home distances measured with these devices being consistent with those obtained manually with clinical 71 guidance. Such tools designed for at-home use are therefore likely to play an increasingly important role in 72 the follow-up of patients with gait disorders. 73

FeetMe[®] insoles are among the recently developed wearable devices that have the capability to allow gait assessments to be self-administered remotely in the patient's own home. These insoles were designed to assess 75 many gait parameters, including stride length, velocity, stance, swing, step, single and double support 76 durations, and cadence. They have already been proven to be as reliable as the GAITRite clinical walkway 77 system for walking tests conducted in clinical settings with healthy volunteers [14], patients post-stroke [15], 78 and in patients with multiple sclerosis [16] and Parkinson's disease [17]. The FeetMe® insoles have also 79 already been found to be a reliable and accurate solution for measuring the 6MWD in hospital settings when 80 compared to the ground truth measured by a surveyor's wheel and estimates made by a rater (A. Mostovov, 81 unpublished observations). The aim of the current study was to assess the reliability and repeatability of 82 FeetMe® insole measurements of the 6MWDs completed by healthy volunteers at home. 83

Materials and Methods

Study design

This single-center, prospective study was conducted between October 2021 and August 2022 by investigators working at the Delafontaine Hospital Center (Saint-Denis, France). The study was approved by 87

84

a French ethics committee, CPP EST I, and complied with the Declaration of Helsinki and all subsequent 88 amendments (registration number, ID-RCB: 2021-A00037-34).

The study was designed to test the reliability of the 6MWDs measured by the connected insoles along a 10-m track remotely at home, compared to that measured for same tests performed in a hospital setting with 91 simultaneous assessment of the 6MWD by the insoles and a rater. 92

All healthy volunteers aged between 18 and 80 years old, who were able to walk 100 m unaided, had no gait disorders, and who were accustomed to using a smartphone, were eligible to participate in the study. 94 Volunteers who had undergone surgery that could potentially impact gait in the previous 3 months (e.g., 95 orthopedic surgery, an intervention for trauma of the lower limbs or spine, gynecological or urological surgery, 96 or brain or spinal cord surgery) and those with a chronic disease affecting walking (e.g., rheumatological, 97 orthopedic, pain, or neurological disorders) were excluded. The volunteers were provided with information 98 about the study by phone or e-mail prior to the study start, and were given the opportunity to ask any the 99 questions. All volunteers provided signed consent prior to the study start. 100

Instrumentation

The study used size 35 to 46 FeetMe[®] insoles (FeetMe SAS, Paris, France), a Class Im CE(93/42/EC) and Class I FDA 510(k) exempt medical device (Fig 1a). The technical characteristics of the insoles have been 104 described previously [14]. The FeetMe[®] insoles were used together with the FeetMe[®] Evaluation smartphone 105



Figure 1. (a) A pair of FeetMe[®] Insoles. (b) to (d) FeetMe[®] Evaluation mobile application interface.

application to administer the 6MWT (Fig 1b to d). Data collected by the FeetMe® insoles were transferred to 106 the smartphone application via a Bluetooth[®] Low Energy (BLE) emitter in the insoles, allowing information 107 on plantar pressure, gait parameters and walking distance to be received in real time. Users selected and 108 launched the 6MWT through the smartphone application. Once the 6MWT had been launched, the application 109 collected and recorded the user's gait parameters for each of their steps over the entire duration of the test, 110 and then automatically stopped recording after 6 minutes and informed the user that the test had been 111 completed. Test results were then displayed in the application or on the associated web platform, the FeetMe[®] 112 Mobility Dashboard. 113

For the 6MWTs performed at home, participants were provided with simple equipment — two hoops (diameter: 0.5 m) attached together with a 10-m string — to allow them to define a 10-m track in their home 115 surroundings. 116

Intervention

Prior to the intervention, all volunteers were given training on the use of the FeetMe® insoles and FeetMe® Evaluation smartphone application so that they could use the system independently, without any support from 119 a nurse or other healthcare professional. The healthy volunteers then wore the insoles while carrying out 120 6MWTs at two hospital visits (baseline: day 0, and Week 1: day 8) and on two occasions at home (baseline: 121 day 1, and Week 1: day 7). 122

For the two tests conducted at the hospital, data were analyzed for each participant as they performed the 6MWTs walking at a comfortable speed on a 10-m track, while wearing the FeetMe[®] insoles and being 124 simultaneously assessed by a rater. Contrary to the official test guidelines [18], no signs of encouragement 125 were provided by the rater during the test. The rater only informed the participant of the time remaining every 126 minute, then 30 seconds and 10 seconds before the end of the test. 127

For the two tests conducted at home, volunteers were provided with the insoles, a smartphone with the FeetMe[®] Evaluation application, and the track equipment. They were asked to perform the 6MWTs while 129 wearing the insoles on a 10-m track made using the equipment provided. The test could be performed in a 130

quiet place either indoors or outdoors (undercover if required by weather conditions), but required a flat and131hard surface, with few or no passages and, ideally, no obstacles.132

Outcomes

The main outcome was comparison of the test-retest reliability of the FeetMe[®] 6MWD measurements from tests performed by the participants at home without any assistance with that of the 6MWD measurements made by the rater in hospital and by FeetMe[®] in hospital.

Statistical analysis

The normality of the 6MWD data was assessed using Q–Q plots and Shapiro-Wilk normality tests. The mean and standard deviation (SD) of the recorded 6MWDs were calculated for the rater at hospital, FeetMe[®] 139 at hospital and FeetMe[®] at home at baseline and Week 1. The bias, the 95% confidence interval (CI) of 140 differences (i.e., limits of agreement), Pearson correlation coefficient, ICC (2,1), coefficient of determination, 141 standard error of the measurement (SEM) and coefficient of variation (CV) were calculated to compare 142 baseline test results with test results obtained at Week 1 for each of the three test configurations. A Levene 143 test was used to assess significant differences between the SDs of the test results at baseline and at Week 1. 144

The repeatability of the test results obtained at the two timepoints was analyzed using Bland-Altman and linear regression plots for all three configurations: rater at hospital, FeetMe[®] at hospital and FeetMe[®] at home. 146

The following criteria were used to assess the degree of correlation [19]: <0.30 negligible, 0.30–0.50 low, 0.50–0.70 moderate, 0.70–0.90 good, and 0.90–1.00 excellent. The same criteria were used for the coefficients 148 of determination. For the ICCs, values below 0.50 were deemed to indicate poor validity, values between 0.50 149 and 0.75 to indicate moderate validity, values between 0.75 and 0.90 to indicate good validity and values 150 greater than 0.90 to indicate excellent validity (as described previously [20]). A priori significance levels (α) 151 were set at 0.05 for all analyses. All data and statistical analyses were performed using Python software 152 (version 3.8). 153

Results

154

133

Demographics and population distribution



Figure 2. Flowchart of participant enrolment and data exclusion. Abbreviation: 6MWT, six-minute walking test.

A total of 33 healthy volunteers, 15 females and 18 males, were included in the study. Participants ranged in age from 23 to 73 years, with a mean of 42 years. The average height and weight of the population were 157 173.9 ± 9.3 cm and 70.9 ± 10.9 kg, respectively. 158



Figure 3. Q-Q plots for the 6MWDs evaluated at baseline and Week 1 by a rater at hospital, and by FeetMe[®] at hospital and at home.

Overall, 30 out of the 33 participants completed all the tests in the hospital setting (Fig 2). Among these 30 participants, one participant performed no tests at home and four performed the test at home on only one 160 out of the two days required. In addition, three of the participants carried out tests that were shorter than 6 161 minutes, and a technical issue prevented data from being recorded in one case. Data from all of these 162 participants were excluded from the analysis and therefore the final analysis population consisted of 21 healthy 163 volunteers.

 Table 1. Mean and standard deviation of the 6MWD measurements obtained at baseline and at Week 1 by the rater and

 FeetMe[®] at hospital and by FeetMe[®] at home.

Test configuration	6MWD at baseline n		baseline	6MWD at Week 1		Shapiro-Wilk p-values*		Levene test	
								p-values**	
		Mean [m]	SD [m]	Mean [m]	SD [m]	Baseline	Week 1		
Rater at hospital	21	410.86	52.60	425.43	57.87	0.09	0.05	0.82	
FeetMe [®] at hospital	21	436.93	52.14	453.20	61.09	0.07	0.06	0.77	
FeetMe [®] at home	21	453.02	67.18	450.87	67.02	0.09	0.004	0.98	

*The Shapiro-Wilk test was used to assess the normality of the data obtained from the three configurations at baseline and at Week 1. **The Levene test p-values were obtained from comparisons between the SDs of the test results at baseline and Week 1. Abbreviations: 6MWD, six-minute walking distance; n, number of participants; SD, standard

Q-Q plots evaluating the normality of the data for each test configuration (rater at hospital, FeetMe[®] at hospital and FeetMe[®] at home) both at baseline and at Week 1, indicated that the distribution of the data was 166 close to normal in all cases (Figure 3). The Shapiro-Wilk tests yielded p-values greater than 0.05 for the data 167 collected at baseline for all three configurations. However, Shapiro-Wilk p-values for the data collected at 168 Week 1 by the rater and by FeetMe[®] at home were equal to or below 0.05 (Table 1).

Repeatability assessments

The mean and SD of the 6MWDs measured at baseline were very similar to those estimated at Week 1 for the FeetMe[®] evaluations conducted at home, but larger differences in the mean and SD values obtained at 172 the two timepoints were observed for the measurements made by the rater and by FeetMe during the hospital 173

visits (Table 1). The results of the Levene test showed that there were no significant differences in the SDs of 174 the distance estimates made at baseline and Week 1 for all three test configurations (Table 1).

Table 2. Analysis of the test–retest reliability of the 6MWD measurements at baseline and Week 1 by the rater, and by

 FeetMe[®] at hospital and FeetMe[®] at home.

Test configuration	n	Bias [m]	Limits of agreement [m]	Coefficie nt of determin ation	Pearson Correlatio n	ICC [lower–upper 95% CI]	SEM [m]	CV [%]
Rater at hospital	21	-14.57	[-81.83-52.69]	0.66	0.81	0.79 [0.54–0.91]	25.65	6.24
FeetMe [®] at hospital	21	-16.27	[-85.29–52.74]	0.67	0.82	0.78 [0.53-0.91]	26.65	6.10
FeetMe [®] at home	21	2.15	[-40.24-44.54]	0.90	0.95	0.95 [0.88–0.98]	15.02	3.33
Rater at hospital FeetMe [®] at hospital FeetMe [®] at home	21 21 21 21	-14.57 -16.27 2.15	[-81.83–52.69] [-85.29–52.74] [-40.24–44.54]	0.66 0.67 0.90	0.81 0.82 0.95	0.79 [0.54–0.91] 0.78 [0.53–0.91] 0.95 [0.88–0.98]	25.65 26.65 15.02	6.24 6.10 3.33

Abbreviations: CI, confidence interval; CV, coefficient of variation; ICC, intraclass correlation coefficient; SEM, standard error of the measurement.

The FeetMe® at home measurements showed a very low test-retest bias of 2.15 m, which was less than



Figure 4. Linear regression plots between the 6MWD evaluated at baseline and Week 1 by the rater at hospital, and by FeetMe[®] at hospital and at home.

0.5% of the total distance measured at both time points (Table 2). In comparison, the equivalent bias for the 177 rater assessment was -14.57 m. The results of the linear regression analysis between the two visits for each 178



Figure 5. Bland-Altman plots between the 6MWD estimated at baseline and at Week 1 by the rater at hospital, and by FeetMe[®] at hospital and at home. The solid lines indicate the bias (mean difference) values, and the dashed lines indicate the upper and lower limits of agreement (95% confidence intervals).

test configuration (rater at hospital, FeetMe® at hospital and FeetMe® at home) are shown in Figure 4. It is 179 noticeable that for FeetMe[®] at home estimates, the regression line was very close to the ideal reference. This 180 observation was further confirmed by the coefficient of determination value of 0.90 and the Pearson 181 correlation coefficient value of 0.95 indicating an excellent level of correlation between the 6MWDs measured 182 at the two timepoints (Table 2). In addition, the 95% CIs of the ICC (0.88–0.98) for the at-home FeetMe® 183 measurements indicated a very good to excellent intraclass correlation between the distances measured by the 184 device at the two timepoints. By contrast, the coefficient of determination value of 0.66 and the Pearson 185 correlation coefficient value of 0.81 indicated that the measurements made by the rater showed a moderate to 186 good correlation between the two timepoints, and the 95% CIs of the ICC (0.54–0.91) indicated a moderate 187 to excellent intraclass correlation for the rater measurements. The SEM and the CV values were also lower 188 for the measurements made during the FeetMe[®] at-home assessments than for those made during the rater 189 assessments at hospital: 15.02 m and 3.33% for FeetMe® at home versus 25.65 m and 6.24 % for the rater, 190 respectively. Analysis of the Bland-Altman plots (Figure 5) confirmed these conclusions: in addition to 191 showing much lower bias, the FeetMe[®] at home estimates showed substantially narrower limits of agreement 192 compared to those for the two in-hospital test configurations. 193

Discussion

This study evaluated the potential of FeetMe[®] insoles, a connected wearable gait assessment device, to provide a solution allowing 6MWTs to be self-administered, independently and accurately, by individuals in 196 their own home. The test-retest reliability of the 6MWDs measured by the FeetMe® insoles during two at-197 home 6MWTs performed within a one-week of interval by healthy participants was compared with that for 198 measurements obtained using the FeetMe[®] insoles in hospital and by a rater in hospital. Our study 199 demonstrated that, while there was good agreement between the test-retest measurements for all three test 200 configurations, the 6MWD measurements made by the FeetMe[®] insoles at home had higher ICC and 201 coefficient of determination values, and lower bias, SEM and CV% values than those obtained for the in-202 hospital FeetMe and rater measurements. Thus, at-home self-administered 6MWTs using the FeetMe® 203 technology were found to be at least, if not more, reliable than rater assessments conducted in a hospital 204 setting, providing strong evidence that the FeetMe® insoles will deliver an easy-to-use, reliable, and accurate 205 solution allowing patients to conduct 6MWTs at home. 206

The performance of FeetMe insoles in this study was assessed in a population of 21 healthy volunteers, aged between 23 and 73 years old. The age range of the study population was therefore wide enough to cover 208 various levels of physical performance. The excellent test-retest ICC value obtained in our study for the at-209 home FeetMe[®] measurements (0.95, 95% CI: [0.88–0.98]) was similar to the ICC values reported previously 210 in the literature for repeated 6MWTs conducted in controlled settings with conventional assessment of the 211 6MWD by a rater (e.g. 0.98, 95% CI: [0.97-0.99] [6] and 0.93 [21]). In contrast, the ICC values obtained for 212 the measurements made by the rater (0.79, 95% CI: [0.54–0.91]) and by the FeetMe[®] device in hospital (0.78, 213 95% CI: [0.53–0.91]) were lower than those reported previously. The CV% values obtained in our study were 214 lower than those reported previously (e.g., 8% [22]) for all three test configurations studied. This difference 215 might be explained by the fact that previous studies involved different populations (frail older adults with 216 dementia [6], patients with chronic obstructive pulmonary disease, COPD [7] or patients with osteoarthritis 217 [22]) with different age ranges from those used in our study, or conducted the assessments on tracks with 218 different lengths, following the official test guidelines. Indeed, the track length of 10 m used in our study was 219 optimized to allow for the test to be conducted in all home environments with minimal equipment. However, 220

the same space constraints may also occur in hospital settings where use of the 30-m track recommended in the official test guidelines is not always feasible. Our study therefore also provides strong evidence validating the use of shorter track lengths in all settings, which should be considered in any future revisions of 6MWT guidelines.

Given the widespread use of the 6MWT in clinical practice for evaluating the functional capacity of patients with a range of diseases, there is great interest in developing technical solutions that could help to 226 streamline the evaluation process, allowing tests to be conducted more frequently and provide more detailed 227 follow-up data and improved care. Several studies have evaluated potential solutions that could allow 6MWTs 228 to be self-administered or performed at home. However, only a few of these studies have involved devices 229 that could provide a complete solution, allowing patients to conduct 6MWTs independently, without 230 supervision by a healthcare professional, and provide estimates of the 6MWD without any assumptions or a 231 priori information. In one of the early studies, Alison et al. highlighted the interest of performing the 6MWT 232 at home in survivors of critical illness [23]. However, in this study the 6MWTs were still administered in the 233 conventional manner, with the rater being dispatched to the patient's home to administer the test, something 234 that is seldomly possible outside of a clinical study. 235

A few of the solutions assessed in previous studies used accelerometer signals to measure gait and focused only on the number of steps taken [12,13,24,25]. These studies either did not include any assessment of the 6MWD, or tried to derive the distance walked based on a priori information such as patient height or average stride length at baseline. However, these derived estimates are prone to error as stride length has been shown to vary over time in patients with pathologies such as stroke, cerebral ataxia or Parkinson's disease, especially after the patient has received physical therapy [26–28].

In a preliminary study conducted in a laboratory setting, Smith-Turchyn et al. evaluated the potential of the EasyMeasure application as an aid for self-administering 6MWTs at home [29]. As part of the 243 experimental design, the participants were responsible for timing the test and had to manually count the laps 244 walked. Although this study was carried out using a healthy population of 20 young university student 245 volunteers, the reported accuracy of the tests conducted using the application was low, and 80% of the 246

participants were found to have deviated from the test instructions (i.e., lost count of the number of laps, did not measure the distance walked, or did not walk at their maximum speed). Thus, given the extent of the test deviations reported in this healthy population, the technology-based method assessed in this study appears unlikely to be suitable for use by elderly people or patients with cognitive difficulties, highlighting the need for a more automated and easy-to-use tool.

The results of the test-retest analyses of the FeetMe[®] at home measurements can be compared to those reported for other systems that have been evaluated for self-administering the 6MWT. Brooks et al. [25] 253 evaluated the performance of a smartphone-based application for assessing 6MWTs conducted at home by 19 254 participants, including patients with congestive heart failure or pulmonary hypertension, and healthy controls. 255 At least three tests with a two-week interval were performed by each participant. Analyses of the results 256 revealed a CV value of 4.7% for the smartphone application, compared to the lower CV value of 3.33% 257 obtained for the FeetMe® device used at home in the current study. One of the most promising previous studies 258 evaluating a solution for carrying out 6MWTs remotely was that by Wevers et al. [30]. This study investigated 259 the use of a global positioning system (GPS) by investigators administering 6MWTs to 27 patients with 260 chronic stroke outdoors in the patients' own neighborhoods [30]. A measuring wheel was also used by the 261 investigators as a reference and the official 6MWT guidelines were followed as closely as possible, including 262 the use of a 30-m track. The results obtained for the reproducibility of the GPS-estimated 6MWDs were very 263 good, with an ICC of 0.96 and an SEM of 18.1 m. Remarkably, the values obtained for the FeetMe[®] device at 264 home in the current study were slightly better for the SEM (15.02 m) and very similar for the ICC (0.95). In 265 addition, although the GPS appeared to provide a well suited and accurate solution for conducting 6MWTs 266 remotely, unlike the FeetMe® system, the GPS cannot be used to conduct the tests indoors. 267

The current study provided the first assessment of the test-retest reliability of FeetMe[®] insoles for measuring 6MWDs during tests conducted independently by the participants at home compared to in hospital 269 settings. However, this study also had some limitations. In particular, this study was carried out using inhospital tests conducted at a single center in a single country and involved healthy volunteers rather than 271 patients with pathological gait. Future studies are therefore required to analyze the results obtained from a 272

larger sample population, including both healthy volunteers and those with gait anomalies, with in-hospital
 tests conducted at multiple centers and in multiple countries. In addition, the learning effect between repeated
 6MWTs at home should be further studied and compared to that in hospital settings [31].

Conclusions

276

285

In conclusion, this study demonstrated that the FeetMe[®] connected insoles provide a reliable solution for allowing 6MWTs to be self-administered independently at home. At-home monitoring of gait would remove 278 the patient burden associated with commuting to hospital assessment centers, and would drastically simplify 279 the patient's care. The home setting would also allow for more frequent assessments of the functional capacity 280 of patients, and therefore result in better patient follow-up and, ultimately, in overall improvements in patient 281 management. In addition, the FeetMe[®] device has the capability of collecting additional information on patient 282 gait parameters during the test, providing complementary data, which when analyzed together with the 283 6MWD, can help obtain a finer understanding of a patient's condition. 284

Acknowledgments

The authors would like to thank all volunteers who agreed to participate in this study. We also thank Margarita Arango, 286 Ayelen Gallardo, Christelle Saulnier and prof Caroline Moreau for proofreading of this manuscript and Gilles Monneret 287 for advising on statistical analysis. We are grateful to Cyril Basquin for data management services, and for his input on 288 the study methodology. We would also like to thank Drs Emma Pilling and Marielle Romet (Santé Active Edition – 289 Synergy Pharm) for medical writing assistance and language editing. 290

References

- Mirelman, A.; Bonato, P.; Camicioli, R.; Ellis, T.D.; Giladi, N.; Hamilton, J.L.; Hass, C.J.; Hausdorff, J.M.; 292 Pelosin, E.; Almeida, Q.J. Gait Impairments in Parkinson's Disease. *Lancet Neurol.* 2019, 18, 697–708, doi:10.1016/S1474-4422(19)30044-4.
- 2. Ataullah, A.H.M.; De Jesus, O. Gait Disturbances. In *StatPearls*; StatPearls Publishing: Treasure Island (FL), 295 2022.
- 3. Butland, R.J.A.; Pang, J.; Gross, E.R.; Woodcock, A.A.; Geddes, D.M. Two-, Six-, and 12-Minute Walking Tests 297 in Respiratory Disease. *BMJ* **1982**, *284*, 1607–1608, doi:10.1136/bmj.284.6329.1607.
- 4. Enright, P.L. The Six-Minute Walk Test. *Respir. Care* **2003**, *48*, 783–785.

- Solway, S.; Brooks, D.; Lacasse, Y.; Thomas, S. A Qualitative Systematic Overview of the Measurement 300 Properties of Functional Walk Tests Used in the Cardiorespiratory Domain. *Chest* 2001, *119*, 256–270, doi:10.1378/chest.119.1.256.
- Chan, W.L.S.; Pin, T.W. Reliability, Validity and Minimal Detectable Change of 2-Minute Walk Test, 6-Minute 303 Walk Test and 10-Meter Walk Test in Frail Older Adults with Dementia. *Exp. Gerontol.* 2019, *115*, 9–18, doi:10.1016/j.exger.2018.11.001.
- Hansen, H.; Beyer, N.; Frølich, A.; Godtfredsen, N.; Bieler, T. Intra- and Inter-Rater Reproducibility of the 6-Minute Walk Test and the 30-Second Sit-to-Stand Test in Patients with Severe and Very Severe COPD. *Int. J. Chron. Obstruct. Pulmon. Dis.* 2018, *Volume 13*, 3447–3457, doi:10.2147/COPD.S174248.
- Cheng, D.K.; Nelson, M.; Brooks, D.; Salbach, N.M. Validation of Stroke-Specific Protocols for the 10-Meter 309 Walk Test and 6-Minute Walk Test Conducted Using 15-Meter and 30-Meter Walkways. *Top. Stroke Rehabil.* 2020, 27, 251–261, doi:10.1080/10749357.2019.1691815.
- Guyatt, G.H.; Pugsley, S.O.; Sullivan, M.J.; Thompson, P.J.; Berman, L.B.; Jones, N.L.; Fallen, E.L.; Taylor, 312 D.W. Effect of Encouragement on Walking Test Performance. *Thorax* 1984, 39, 818–822, doi:10.1136/thx.39.11.818.
- Weir, N.A.; Brown, A.W.; Shlobin, O.A.; Smith, M.A.; Reffett, T.; Battle, E.; Ahmad, S.; Nathan, S.D. The 315 Influence of Alternative Instruction on 6-Min Walk Test Distance. *Chest* 2013, 144, 1900–1905, doi:10.1378/chest.13-0287.
- Ibrahim, A.A.; Küderle, A.; Gaßner, H.; Klucken, J.; Eskofier, B.M.; Kluge, F. Inertial Sensor-Based Gait 318 Parameters Reflect Patient-Reported Fatigue in Multiple Sclerosis. *J. NeuroEngineering Rehabil.* 2020, *17*, 1–9, doi:10.1186/s12984-020-00798-9.
- Jehn, M.; Prescher, S.; Koehler, K.; von Haehling, S.; Winkler, S.; Deckwart, O.; Honold, M.; Sechtem, U.; 321 Baumann, G.; Halle, M.; et al. Tele-Accelerometry as a Novel Technique for Assessing Functional Status in Patients with Heart Failure: Feasibility, Reliability and Patient Safety. *Int. J. Cardiol.* 2013, *168*, 4723–4728, doi:10.1016/j.ijcard.2013.07.171.
- Burch, A.E.; Scherr, D.; Rieth, A.; Griffin, J.; Bianco, N.R.; Odeneg, T.; Sears, S.F. Wearable Cardioverter 325 Defibrillator-Guided 6-Min Walk Test Performed at Home Is Accurate and Reliable: RESULTS OF THE TRENDS STUDY. J. Cardiopulm. Rehabil. Prev. 2020, 40, E14–E17, doi:10.1097/HCR.00000000000441.
- 14. Jacobs, D.; Farid, L.; Ferré, S.; Herraez, K.; Gracies, J.M.; Hutin, E. Evaluation of the Validity and Reliability of 328 Connected Insoles to Measure Gait Parameters in Healthy Adults. *Sensors* **2021**, *21*, 1–14, doi:10.3390/s21196543.
- Farid, L.; Jacobs, D.; Do Santos, J.; Simon, O.; Gracies, J.-M.; Hutin, E. FeetMe® Monitor-Connected Insoles 330 Are a Valid and Reliable Alternative for the Evaluation of Gait Speed after Stroke. *Top. Stroke Rehabil.* 2021, 28, 127–134, doi:10.1080/10749357.2020.1792717.
- Granja Domínguez, A.; Romero Sevilla, R.; Alemán, A.; Durán, C.; Hochsprung, A.; Navarro, G.; Páramo, C.;
 Venegas, A.; Lladonosa, A.; Ayuso, G.I. Study for the Validation of the FeetMe® Integrated Sensor Insole System Compared to GAITRite® System to Assess Gait Characteristics in Patients with Multiple Sclerosis. *PLOS ONE* 2023, *18*, e0272596, doi:10.1371/journal.pone.0272596.
- Parati, M.; Gallotta, M.; Muletti, M.; Pirola, A.; Bellafà, A.; De Maria, B.; Ferrante, S. Validation of Pressure-Sensing Insoles in Patients with Parkinson's Disease during Overground Walking in Single and Cognitive Dual-Task Conditions. *Sensors* 2022, *22*, 6392, doi:10.3390/s22176392.
- 18. ATS Statement: Guidelines for the Six-Minute Walk Test. Am. J. Respir. Crit. Care Med. 2002, 166, 111–117, 340 doi:10.1164/ajrccm.166.1.at1102.
- Mukaka, M.M. Statistics Corner: A Guide to Appropriate Use of Correlation Coefficient in Medical Research. 342 Malawi Med. J. J. Med. Assoc. Malawi 2012, 24, 69–71.

- Koo, T.K.; Li, M.Y. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability 344 Research. J. Chiropr. Med. 2016, 15, 155–163, doi:10.1016/j.jcm.2016.02.012.
- Hernandes, N.A.; Wouters, E.F.M.; Meijer, K.; Annegarn, J.; Pitta, F.; Spruit, M.A. Reproducibility of 6-Minute 346 Walking Test in Patients with COPD. *Eur. Respir. J.* 2011, *38*, 261–267, doi:10.1183/09031936.00142010.
- Naylor, J.M.; Hayen, A.; Davidson, E.; Hackett, D.; Harris, I.A.; Kamalasena, G.; Mittal, R. Minimal Detectable 348 Change for Mobility and Patient-Reported Tools in People with Osteoarthritis Awaiting Arthroplasty. *BMC Musculoskelet. Disord.* 2014, *15*, 235, doi:10.1186/1471-2474-15-235.
- Alison, J.A.; Kenny, P.; King, M.T.; McKinley, S.; Aitken, L.M.; Leslie, G.D.; Elliott, D. Repeatability of the Six-Minute Walk Test and Relation to Physical Function in Survivors of a Critical Illness. *Phys. Ther.* 2012, 92, 1556– 1563, doi:10.2522/ptj.20110410.
- Rens, N.; Gandhi, N.; Mak, J.; Paul, J.; Bent, D.; Liu, S.; Savage, D.; Nielsen-Bowles, H.; Triggs, D.; Ata, G.; et al. Activity Data from Wearables as an Indicator of Functional Capacity in Patients with Cardiovascular Disease. *PLOS ONE* 2021, *16*, e0247834, doi:10.1371/journal.pone.0247834.
- Brooks, G.C.; Vittinghoff, E.; Iyer, S.; Tandon, D.; Kuhar, P.; Madsen, K.A.; Marcus, G.M.; Pletcher, M.J.; Olgin, J.E. Accuracy and Usability of a Self-Administered 6-Minute Walk Test Smartphone Application. *Circ. Heart Fail.* 2015, *8*, 905–913, doi:10.1161/CIRCHEARTFAILURE.115.002062.
- Munari, D.; Pedrinolla, A.; Smania, N.; Picelli, A.; Gandolfi, M.; Saltuari, L.; Schena, F. High-Intensity Treadmill 360 Training Improves Gait Ability, VO2peak and Cost of Walking in Stroke Survivors: Preliminary Results of a Pilot Randomized Controlled Trial. *Eur. J. Phys. Rehabil. Med.* 2018, *54*, doi:10.23736/S1973-9087.16.04224-6.
- Triegaardt, J.; Han, T.S.; Sada, C.; Sharma, S.; Sharma, P. The Role of Virtual Reality on Outcomes in 363 Rehabilitation of Parkinson's Disease: Meta-Analysis and Systematic Review in 1031 Participants. *Neurol. Sci.* 2020, 41, 529–536, doi:10.1007/s10072-019-04144-3.
- Keller, J.L.; Bastian, A.J. A Home Balance Exercise Program Improves Walking in People With Cerebellar Ataxia. 366 Neurorehabil. Neural Repair 2014, 28, 770–778, doi:10.1177/1545968314522350.
- 29. Smith-Turchyn, J.; Adams, S.C.; Sabiston, C.M. Testing of a Self-Administered 6-Minute Walk Test Using 368 Technology: Usability, Reliability and Validity Study. *JMIR Rehabil. Assist. Technol.* 2021, *8*, e22818, doi:10.2196/22818.
- Wevers, L.; Kwakkel, G.; van de Port, I. Is Outdoor Use of the Six-Minute Walk Test with a Global Positioning 371 System in Stroke Patients' Own Neighbourhoods Reproducible and Valid? *J. Rehabil. Med.* 2011, 43, 1027–1031, doi:10.2340/16501977-0881.
- Holland, A.E.; Spruit, M.A.; Troosters, T.; Puhan, M.A.; Pepin, V.; Saey, D.; McCormack, M.C.; Carlin, B.W.;
 Sciurba, F.C.; Pitta, F.; et al. An Official European Respiratory Society/American Thoracic Society Technical Standard: Field Walking Tests in Chronic Respiratory Disease. *Eur. Respir. J.* 2014, *44*, 1428–1446, doi:10.1183/09031936.00150314.



 Select a test 	← 6m	inutes
Dynamic Static Import		3
6-minute >		
S 25-foot	02	:00
b to-meter >		-
400-meter >	120	100.3
Free walking >	Distance (m)	Velocity (cm/s)
	Stride Length (on)	118
	Take	a break
	Stop the	e exercise

(c)

(b)



(d)







